SMMT · Summit Therapeutics PLC

-

Please sign in to comment on SMMT

1 Comment

Admin

4 years ago

Summit Therapeutics Inc is currently in a long term uptrend where the price is trading 32.2% above its 200 day moving average.

From a valuation standpoint, the stock is 61.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 521.4.

Summit Therapeutics Inc's total revenue rose by 128.8% to $366K since the same quarter in the previous year.

Its net income has increased by 99.7% to $-29K since the same quarter in the previous year.

Finally, its free cash flow fell by 270.7% to $-23M since the same quarter in the previous year.

Based on the above factors, Summit Therapeutics Inc gets an overall score of 4/5.

ISIN	US86627T1088
Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
Industry	Biotechnology

Market Cap	27B
PE Ratio	None
Target Price	35.4953
Beta	-0.46
Dividend Yield	None

ABOUT

Summit Therapeutics PLC

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

SMMT · Summit Therapeutics PLC

-

Summit Therapeutics PLC

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Summit Therapeutics PLC using a moving average strategy